secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001193125-25-133773
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics prices $50M public offering of warrants; cash runway through Q3 2026
--------------------------------------------------------------------------------

- Net proceeds of ~$46.6M from offering of pre-funded warrants and Series A/B/C warrants, priced at $0.7499 per unit.
- Cash runway extended to Q3 2026, assuming no contributions from AbbVie or Gilead partnerships.
- Series A warrants exercisable after Dec 1, 2025 or if stock closes above $1.50 for five days; $0.75 exercise price.
- Series B and C warrants subject to offset/cancellation if non-dilutive capital ≥$20M received before Dec 1, 2026.
- If all Series B and C warrants exercised for cash, additional gross proceeds up to ~$100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525133773/0001193125-25-133773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525133773/d88500d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-133773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer